|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 880.10 INR | -2.55% |
|
-1.06% | +47.04% |
Business description: Granules India Limited
Number of employees: 4,306
Sales by Activity: Granules India Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Pharmaceutical Products | 37.65B | 45.12B | 45.06B | 44.82B | 53.66B |
Geographical breakdown of sales: Granules India Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Outside India | - | 42.22B | 42.81B | 42.11B | 51.44B |
India | 4.52B | 2.9B | 2.26B | 2.71B | 2.22B |
ROW | 1.88B | - | - | - | - |
North America | 19.58B | - | - | - | - |
Latin America | 3.76B | - | - | - | - |
Europe | 7.91B | - | - | - | - |
Executive Committee: Granules India Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 30/07/2025 | |
| President | - | 13/10/2024 | |
Mukesh Surana
DFI | Director of Finance/CFO | 46 | 29/12/2022 |
Sanjay Kumar
PSD | President | - | 31/08/2023 |
P.V. Srinivas
CTO | Chief Tech/Sci/R&D Officer | - | - |
Composition of the Board of Directors: Granules India Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 20/08/2013 | |
| Director/Board Member | 42 | 31/12/2004 | |
| Director/Board Member | 66 | 30/05/2012 | |
| Director/Board Member | 72 | 18/02/2013 | |
Arun Sawhney
BRD | Director/Board Member | 70 | 28/10/2018 |
| Director/Board Member | 64 | 12/12/2021 | |
| Director/Board Member | 60 | 21/12/2021 | |
| Director/Board Member | 68 | 15/05/2023 | |
| Director/Board Member | 67 | 22/01/2024 | |
| Director/Board Member | - | 22/01/2024 |
Company details: Granules India Limited
Group companies: Granules India Limited
| Name | Category and Sector |
|---|---|
Granules Pharmaceuticals, Inc.
 Granules Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical manufacturing & marketing |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.55% | -1.06% | +77.46% | +183.99% | 2.26B | |
| +0.85% | -0.80% | +52.79% | +161.33% | 1,051B | |
| +1.23% | -1.53% | +54.58% | +59.08% | 609B | |
| +0.04% | +2.58% | +34.47% | +86.33% | 450B | |
| +0.78% | -0.71% | +29.28% | +24.10% | 330B | |
| +1.41% | +0.58% | +35.44% | +40.67% | 284B | |
| -0.27% | -1.87% | +22.34% | +22.51% | 263B | |
| -1.76% | +2.37% | -20.43% | -38.00% | 223B | |
| -1.42% | +0.80% | +24.27% | +57.50% | 198B | |
| -1.48% | +3.43% | +24.08% | +71.67% | 167B | |
| Average | -0.32% | +0.38% | +33.43% | +66.92% | 357.73B | |
| Weighted average by Cap. | +0.37% | +0.02% | +37.54% | +79.70% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GRANULES Stock
- Company Granules India Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition